Clinical Case Database / Category: Case Based Discussion
Metastatic carcinoma of unknown primary
Dr Daniel Krell MRCP, BSc
Foundation Years Journal, volume 4, issue 4, p.20 (123Doc Education, London, April 2010)
Metastatic carcinoma of unknown primary (CUP) accounts for 2â€“4% of all malignancies. Patients present with metastatic disease, but despite standard investigations, the primary site often cannot be located. The prognosis is poor, except in a few specific subgroups, and response to chemotherapy remains disappointing. Patients often initially present with symptoms of metastatic cancer to their GP or A&E and are admitted to hospital under acute medical or surgical teams for investigation, before being referred to oncology services for treatment once a diagnosis has been made. This case-based discussion illustrates a typical case of a patient who presents with CUP and outlines the process by which the patient should be investigated, and referred to the oncology services. The importance of involving multidisciplinary team members is highlighted and the process of breaking bad news is discussed. The use of novel molecular diagnostic techniques is also described.
Access the Clinical Cases Database
A subscription is required to read the full article. Please subscribe using one of the options below.
|Foundation Years Clinical Cases Database||£29.00||6 months|
|Foundation Years Clinical Cases Database||£39.00||12 months|
Dr Daniel Krell MRCP, BSc
Specialist Registrar in Oncology in Royal Free Hospital London
Academic Department of Oncology
Royal Free Hospital
1. Bridgewater J, van Laar R, Floore A, Van't Veer L (2008) British Journal of Cancer, 98:1425â€“1430.
2. Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomised phase II study â€“ trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol, 21:3479â€“3482.
3. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, Mooney J, Verbeke C, Bellamy C, Keith WN, Oien KA (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res, 11:3766â€“3772.
4. Greco FA, Burris III HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin Jr. DC, Erland JB, Morrissey LH, Hainsworth JD (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl cancer research network study. J Clin Oncol, 20:1651â€“1656.
5. Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, U Kaiser U, Aldaoud A and Jahn A (2009) Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. British Journal of Cancer, 100:44â€“49.
6. Levi F, Te VC, Erler G, Randimbison L, La VC (2002) Epidemiology of unknown
primary tumours. Eur J Cancer, 38:1810â€“1812.
7. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer, 39:1990â€“2005.
8. Pavlidis N, Fizazi K (2005) Cancer of unknown primary (CUP). Crit Rev Oncol Hematol, 54:243â€“250.
9. Pittman B, Olver I, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ and Price TJ (2006) Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative Study. British Journal of Cancer, 95:1309â€“1313.
Conflict Of Interest
The Journal requires that authors disclose any potential conflict of interest that they may have. This is clearly stated in the Journal’s published “Guidelines for Authors”. The Journal follows the Guidelines against Conflict of Interest published in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/urm_full.pdf).
The authors of this article have not been paid. The Journal is financed by subscriptions and advertising. The Journal does not receive money from any other sources. The decision to accept or refuse this article for publication was free from financial considerations and was solely the responsibility of the Editorial Panel and Editor-in-Chief.
Patient Consent statement
All pictures and investigations shown in this article are shown with the patients’ consent. We require Authors to maintain patients’ anonymity and to obtain consent to report investigations and pictures involving human subjects when anonymity may be compromised. The Journal follows the Guidelines of the Uniform Requirements for Manuscripts (http://www.icmje.org/urm_full.pdf). The Journal requires in its Guidelines for Authors a statement from Authors that “the subject gave informed consent”.
Animal & Human Rights
When reporting experiments on human subjects, the Journal requires authors to indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the HelsinkiDeclaration of 1975, as revised in 2008.
About the Clinical Cases Database
The Foundation Years Clinical Cases Database is a selection of 600 peer-reviewed clinical cases in the field of patient safety and clinical practice, specifically focused on the clinical information needs of junior doctors, based around the Foundation Year Curriculum programme (MMC). The cases have been chosen to align with the Foundation Year Curriculum.
The database is fully searchable, or can be browsed by medical specialty. Abstracts can be read free of charge, however a subscription is required in order to read the complete cases.